Summary & Overview
CPT 0217U: Genomic Unity Comprehensive Ataxia Repeat Expansion and Sequence
CPT code 0217U designates a Proprietary Laboratory Analyses (PLA) test: Genomic Unity® Comprehensive Ataxia Repeat Expansion and Sequence from Variantyx Inc. The code captures a single-manufacturer laboratory assay that combines repeat expansion detection and sequencing to support genetic diagnosis of ataxia. PLA codes like 0217U matter nationally because they identify unique commercial tests with specific clinical indications, affecting coding consistency, payer coverage determinations, and laboratory billing workflows for rare neurologic disorders.
Key payers in the scope of national analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical purpose of the test, payer coverage landscape summaries, and benchmarks relevant to PLA-coded genetic assays. The publication also provides context on coding implications for laboratory claims, expected sites of service, and considerations for clinicians ordering specialized genetic diagnostics.
This report is intended for revenue cycle professionals, laboratory directors, and clinicians involved in genetic testing procurement and billing. It highlights clinical context for ataxia testing, how a PLA designation shapes administrative handling, and where to look for payer-specific coverage information. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0217U is a Proprietary Laboratory Analyses (PLA) code that applies to a single, unique laboratory test: Genomic Unity® Comprehensive Ataxia Repeat Expansion and Sequence from Variantyx Inc. The analysis combines repeat expansion testing and sequencing to help establish a genetic diagnosis for patients with suspected ataxia.
-
Service type: Proprietary laboratory genetic testing (comprehensive ataxia repeat expansion and sequencing)
-
Typical site of service: Clinical diagnostic laboratory; specimens are submitted from outpatient clinics, neurology practices, and hospital-based providers for laboratory processing and analysis.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to a neurology clinic with progressive balance impairment, unsteady gait, dysarthria, and possibly family history of neurodegenerative movement disorders. The clinician documents a workup for suspected hereditary or sporadic ataxia after neurologic exam and initial imaging (MRI brain) and metabolic screening are nondiagnostic. A blood sample is collected in the outpatient clinic or ambulatory phlebotomy lab and shipped to Variantyx Inc. for the Genomic Unity® Comprehensive Ataxia Repeat Expansion and Sequence test (0217U). Results include repeat expansion analysis and sequencing of ataxia-associated genes and inform diagnosis, genetic counseling, and management planning. Typical sites of service include outpatient neurology clinics, specialty genetic testing laboratories, and ambulatory phlebotomy centers. The clinical workflow: referral by neurologist → pre-test counseling and consent → specimen collection and ordering of 0217U → specimen shipment to the lab → laboratory processing and reporting of repeat expansion and sequencing results → disclosure of results by ordering clinician and genetic counseling as indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Rarely used; applies when no other modifier is appropriate for PLA reporting. |
22 | Increased Procedural Services | Use if documentation supports substantially greater technical effort or interpretation beyond typical processing (rare for PLA). |
26 | Professional Component | Use when only the professional component (interpretation) of the test is billed separately from the lab technical component. |
52 | Reduced Services | Use when the testing service is partially reduced or not fully performed per documentation. |
53 | Discontinued Procedure | Use if testing was initiated but discontinued prior to completion and billing is appropriate. |
62 | Two Surgeons | Not commonly applicable; may be appended if two qualified providers share responsibility for interpretation in unusual workflow. |
78 | Return to Operating Room | Not applicable to routine PLA testing; reserved for surgical procedures when required. |
80 | Assistant Surgeon | Generally not applicable; included when an assistant performs a billable component of a related service. |
AS | Physician Assistant, Nurse Practitioner, or Clinical Nurse Specialist Services | Use when a PA/NP/CNS provides the professional component or ordering/interpretation under appropriate supervision. |
QK | Medical Direction of Two, Three, or Four Certified Anesthesiologists | Not applicable to this lab test but included in common modifier lists. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 163W00000X | Neurology | Ordering providers commonly include neurologists diagnosing ataxia. |
| 2085P0200X | Clinical Molecular Genetics | Laboratory directors and specialists performing genomic interpretation. |
| 208D00000X | Clinical Laboratory | Laboratories performing testing and technical processing of 0217U. |
| 207RC0000X | Medical Genetics & Genomics | Medical geneticists involved in interpretation and counseling. |
| 363L00000X | Genetic Counseling | Genetic counselors who provide pre- and post-test counseling and result disclosure. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
G11.1 | Early-onset cerebellar ataxia | Genetic ataxia subtype commonly evaluated with repeat expansion and sequencing testing such as 0217U. |
G11.3 | Hereditary spastic paraplegia | Some presentations overlap with ataxia; genetic testing can clarify diagnosis. |
G11.4 | Cerebellar ataxia, unspecified | Used when clinical features of ataxia are present but etiology is unknown; supports ordering comprehensive genetic testing. |
R27.0 | Ataxia, unspecified | Symptom code indicating ataxia warranting diagnostic genetic evaluation. |
G31.8 | Other specified degenerative diseases of nervous system | Used when neurodegenerative processes with ataxic features are suspected and genetic testing is indicated. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
81479 | Unlisted molecular pathology procedure | May be used for novel or supplemental molecular testing not captured by existing PLA codes when additional analyses are required. |
88360 | Interpretation and report of molecular pathology procedures | Used by pathologists or molecular specialists to bill professional interpretation when separate from the lab technical component. |
81002 | Urinalysis, non-automated, without microscopy (qualitative) | Example of ancillary tests that may be ordered during a neurologic workup; not specific to ataxia testing but commonly available in outpatient evaluations. |
82947 | Glucose; quantitative, blood (except reagent strip) | Metabolic screening tests sometimes performed as part of broader neurologic evaluation prior to or concurrent with genetic testing. |
96372 | Therapeutic, prophylactic, or diagnostic injection (specify drug) | Represents potential supportive interventions during clinic visits; not directly tied to 0217U but commonly present in clinic billing workflows. |